Synthesis and anti-cancer activity of chalcone linked imidazolones

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 16, 2010, Pages 4865-4869

  Kamal, Ahmed ^a   Ramakrishna, G ^a   Raju, P ^a   Viswanath, A ^a   Janaki Ramaiah, M ^a   Balakishan, G ^a   Pal Bhadra, Manika ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Anti cancer activity; Cell cycle arrest; Chalcone linked imidazolones; G0 G1; G2 M

Indexed keywords

1 (3 AMINOPHENYL) 3 (3,4,5 TRIMETHOXYPHENYL) 2 PROPEN 1 NE; CHALCONE DERIVATIVE; COMBRETASTATIN A4; COMBRETASTATIN A6; COMBRETASTATIN A8; IMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHALCONE; IMIDAZOLONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; CHEMISTRY; DRUG SCREENING; NEOPLASMS; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHALCONE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMIDAZOLES; NEOPLASMS;

EID: 77955429772     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.06.097     Document Type: Article

References (24)

1. G.R. Petitt, G.M. Gragg, D.L. Herald, J.M. Schmidt, and P. Lohavanijaya Can. J. Chem. 60 1982 1374
2. A.T. Mc Gown, and B.W. Fox Cancer Chemother. Pharmacol. 26 1990 79
3. S.L. Young, and D.J. Chaplin Expert Opin. Invest. Drugs 13 2004 1171
4. G.R. Petitt, C. Temple Jr., V.L. Narayanan, R. Varma, and M.J. Simpson Anti-cancer Drug Des. 10 1995 299
5. G.R. Petitt, M.R. Rhodes, D.L. Herald, D.J. Chaplin, M.R.L. Stratford, E. Hamel, R.K. Petitt, J. Chapuis, and D. Oliva Anti-cancer Drug Des. 13 1998 981
6. N.H. Nam, Y. Kim, Y.-J. You, D.-H. Hong, H.-M. Ki, and B.-Z. Ahn Bioorg. Med. Chem. Lett. 11 2001 3073
7. S.J. Won, C.-T. Liu, L.-T. Tsao, J.-R. Weng, H.-H. Ko, J.-P. Wang, and C.-N. Lin Eur. J. Med. Chem. 40 2005 103
8. H.-K. Hsieh, L.-T. Tsao, J.-P. Wang, and C.-N. Lin J. Pharm. Pharm. 52 2000 163
9. S. Mukerjee, V. Kumar, A.K. Prasad, H.G. Raj, M.E. Bracke, C.E. Olsen, S.C. Jain, and V.S. Parmar Bioorg. Med. Chem. 9 2001 337
10. V.S. Parmar, S.C. Jain, K.S. Bisht, N.K. Sharma, S. Himanshu Gupta, A.K. Prasad, A. Jha, S. Poonam Malhotra, S.K. Sharma, M.E. Brache, W. Errington, C.E. Olsen, and J. Wengel Indian J. Chem., Sect. B 37 1998 628
11. S.F. Nielsen, T. Boesen, M. Larsen, K. Schonnig, and H. Kromann Bioorg. Med. Chem. 12 2004 3047
12. S. Ducki, R. Forrest, J.A. Hadfield, A. Kendall, N.J. Lawrence, A.T. Mc Gown, and D. Rennison Bioorg. Med. Chem. Lett. 8 1998 1051
13. N.J. Lawrence, A.T. Mc Gown, S. Ducki, and J.A. Hadfield Anti-cancer Drug Des. 15 2000 135
14. A.R. Siamaki, D.A. Black, and B.A. Arndtsen J. Org. Chem. 73 2008 1135
15. L. Fang, Q. He, Y. Hu, and B. Yang Cancer Chemother. Pharmacol. 59 2007 397
16. Z. Lai, T. Yang, Y.B. Kim, T.M. Sielecki, M.A. Diamond, P. Strack, M. Rolfe, M. Caligiuri, P.A. Benfield, K.R. Auger, and R.A. Copleland PNAS 99 2002 14734
17. J.R. Wu-Wong, J.D. Alder, L. Alder, D.J. Burns, E.K-H. Han, B. Credo, S.K. Tahir, B.D. Dayton, P.J. Ewing, and W.J. Chiou Cancer Res. 61 2001 1486
18. C. Congiu, M.T. Cocco, and V. Onnis Bioorg. Med. Chem. Lett. 18 2008 989
19. S.K. Kumar, E. Hager, C. Petitt, H. Gurulingappa, N.E. Davidson, and S.R. Khan J. Med. Chem. 46 2003 2813
20. D.N. Dhar, and J.B. Lal J. Org. Chem. 23 1958 1159
21. +; purity 95%, C18 column, acetonitrile-water (mobile phase), wavelength 289 nm; yellow solid.
22. P. Luo, Q. He, X. He, Y. Hu, W. Lu, Y. Cheng, and B. Yang Mol. Cancer Ther. 5 2006 962
23. D. Twiddy, G.M. Cohen, M. MacFarlane, and K. Cain J. Biol. Chem. 281 2006 3876
24. L.M. Mooney, K. Al-Sakkaf, B.L. Brown, and P.R.M. Dobson Br. J. Cancer 87 2002 907